Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Bioheart, Inc. (BHRT) Receives Notice of Allowance for Nine New Patent Claims

BioHeart is a biotechnology corporation that develops devices designed to aid in the diagnosis, monitoring, and treatment of cardiovascular diseases. The company aims to improve heart disease sufferers’ quality of life, while attempting to reduce the normally exorbitant costs associated with cardiologic treatments.

In a press statement issued on Thursday, the company announced that it had received a United States Patent and Trademark Office Notice of Allowance for nine new patent claims, which pertain to using electrical signals to stimulate heart cell regeneration. BioHeart’s new technologies are a significant step forward in the field of cardiovascular treatment in that they utilize fundamental electro-chemical genetic instructions to “teach” undifferentiated stem cells to grow into heart muscle. This process will aid heart failure victims in regrowing damaged heart tissue, and could potentially save lives.

“The best way to predict the future is to create it,” said BioHeart’s director of surgical and clinical research, Juan Chachques, “This invention could be regarded in the future as one of the most important developments ever in the fight to reduce the death rate from heart failure.”

BioHeart currently holds the rights to thirty-six related U.S. patents, and has submitted claims for over four hundred.

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *